{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:42:05Z","timestamp":1792233725060,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cgh.2026.08.030","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:47:44Z","timestamp":1788882464000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Noninvasive Test Dynamics Serve as Surrogate End Points for Histologic Improvement in Metabolic Dysfunction\u2013Associated Steatohepatitis? A Systematic Review and Bayesian Meta-Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9049-0996","authenticated-orcid":false,"given":"Pedro Robson","family":"Passos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert Oliveira","family":"Costa Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"de Faria Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Boechat","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Corr\u00eaa","family":"S\u00fcffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Grossi","family":"Lopes Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.08.030_bib1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: hepatology","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-89293-6","article-title":"Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults","volume":"15","author":"Chung","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2026.08.030_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.08.030_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cgh.2024.07.045","article-title":"AcFibroMASH index for the diagnosis of fibrotic MASH and prediction of liver-related events: an international multicenter study","volume":"23","author":"Feng","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib9","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: november 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","article-title":"Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"11","author":"Li","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cgh.2026.08.030_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cgh.2026.08.030_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323695","article-title":"Complications of image-guided liver biopsies: results of a nationwide database analysis","volume":"20","author":"Graf","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.08.030_bib14","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.08.030_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2025.09.019","article-title":"Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials","volume":"84","author":"Lackner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","article-title":"Liver biopsy evaluation in MASH drug development: think thrice, act wise","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib17","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/liv.15914","article-title":"Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-an individual participant data meta-analysis","volume":"44","author":"M\u00f3zes","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.08.030_bib18","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/HEP.0000000000001658","article-title":"Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease","volume":"84","author":"Zhang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib21","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib22","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.cgh.2025.12.001","article-title":"Expert Delphi consensus on surrogate endpoints for treatment assessment in metabolic dysfunction-associated steatohepatitis","volume":"24","author":"Sanyal","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.70376","article-title":"Exploration of multiple non-invasive tests for assessing response to treatment in a semaglutide phase 2b trial in patients with MASH","volume":"63","author":"Nitze","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.08.030_bib24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000001509","article-title":"Non-invasive tests: establishing efficacy for metabolic dysfunction\u2013associated steatohepatitis beyond the biopsy\u2014Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration","volume":"84","author":"Anania","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib27","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/jama.2024.4175","article-title":"Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments","volume":"331","author":"Wallach","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.08.030_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/sim.7561","article-title":"Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials","volume":"37","author":"Baker","year":"2018","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2023.111242","article-title":"Surrogate endpoints: a key concept in clinical epidemiology","volume":"167","author":"Christensen","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cgh.2026.08.030_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.cgh.2026.08.030_bib32","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1002\/sim.9840","article-title":"Covariate adjustment in randomized clinical trials with missing covariate and outcome data","volume":"42","author":"Chang","year":"2023","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib33","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1177\/09622802211047348","article-title":"Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis","volume":"30","author":"Cai","year":"2021","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.cgh.2026.08.030_bib34","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2026.08.030_bib35","series-title":"Bayesian approaches to clinical trials and health-care evaluation","first-page":"408","author":"Spiegelhalter","year":"2003"},{"key":"10.1016\/j.cgh.2026.08.030_bib36","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.cgh.2026.08.030_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102156","article-title":"Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials","volume":"63","author":"Zhang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cgh.2026.08.030_bib38","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cgh.2026.08.030_bib39","article-title":"Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis","volume":"4","author":"Leite","year":"2025","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.cgh.2026.08.030_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/PAP.0000000000000312","article-title":"Regression of hepatic fibrosis and evolution of cirrhosis: a concise review","volume":"28","author":"Khan","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.cgh.2026.08.030_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"Brms: an R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cgh.2026.08.030_bib42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jval.2025.01.005","article-title":"A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis","volume":"28","author":"Vickers","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2026.08.030_bib43","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib44","series-title":"Institute for quality and efficiency in health care: executive summaries","article-title":"Validity of surrogate endpoints in oncology: executive summary of rapid report A10-05, Version 1.1","year":"2005"},{"key":"10.1016\/j.cgh.2026.08.030_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/03009734.2012.668143","article-title":"Regression dilution bias: tools for correction methods and sample size calculation","volume":"117","author":"Berglund","year":"2012","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.cgh.2026.08.030_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2307\/352857","article-title":"Interpreting logistic regression results: a critical commentary","volume":"52","author":"DeMaris","year":"1990","journal-title":"J Marriage Fam"},{"key":"10.1016\/j.cgh.2026.08.030_bib47","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib49","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib50","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib53","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2026.08.030_bib55","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib56","article-title":"Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib57","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib59","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib60","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib62","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib63","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2026.08.030_bib66","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.08.030_bib68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib70","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib71","article-title":"Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial","volume":"5","author":"Brown","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.08.030_bib72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib73","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.08.030_bib74","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.08.030_bib75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: a randomized controlled study","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cgh.2026.08.030_bib76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib77","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib78","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib79","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib81","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib83","first-page":"1","article-title":"Accelerating MASH trials: from biopsy to biomarkers","volume":"11","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-S1-A93","article-title":"Statistical validation of surrogate outcome measures","volume":"12","author":"Buyse","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.cgh.2026.08.030_bib85","article-title":"Evaluation methods for T-association of a surrogate endpoint [Internet]","author":"Hung","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.cgh.2026.08.030_bib86","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib87","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/HEP.0000000000001356","article-title":"Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction","volume":"83","author":"van Kleef","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/HEP.0000000000001421","article-title":"Biopsy-free endpoints in MASH trials: a comparative look at MASHResInd and FAST","volume":"83","author":"Ravaioli","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib89","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.cgh.2026.08.030_bib90","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/00365513.2025.2559352","article-title":"Age- and sex-specific reference values for FIB-4 derived from the Nordic Reference Interval Project (NORIP)","volume":"85","author":"Hamelius","year":"2025","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.cgh.2026.08.030_bib91","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc22-0556","article-title":"Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: impact of diabetes and obesity on FIB-4 score accuracy","volume":"45","author":"Kim","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2026.08.030_bib92","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.08.030_bib93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and surrogate markers: an FDA perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.cgh.2026.08.030_bib94","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/00365521.2011.558112","article-title":"Percutaneous liver biopsy: patients\u2019 point of view","volume":"46","author":"Fern\u00e1ndez-Salazar","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.08.030_bib95","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/HEP.0000000000001396","article-title":"Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy","volume":"83","author":"Loomba","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.08.030_bib96","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14309\/ajg.0000000000003432","article-title":"ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease","volume":"121","author":"Alkhouri","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.08.030_bib97","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.242564","article-title":"Metabolic dysfunction-associated steatotic liver disease at quantitative US: international prospective study","volume":"316","author":"Huang","year":"2025","journal-title":"Radiology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526006695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526006695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:51:20Z","timestamp":1792230680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526006695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"alternative-id":["S1542356526006695"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.08.030","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Noninvasive Test Dynamics Serve as Surrogate End Points for Histologic Improvement in Metabolic Dysfunction\u2013Associated Steatohepatitis? A Systematic Review and Bayesian Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}